reports
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all pro...
EQS-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share 19.03.2025 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Media release of March 19, 2025 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted i...
EQS-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträg...
EQS-News: BB BIOTECH AG / Schlagwort(e): Hauptversammlung/Dividende Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 1.80 pro Aktie 19.03.2025 / 17:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Medienmitteilung vom 19. März 2025 Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 1.80 pro Aktie An der ordentlichen Generalversammlung der BB Biotech AG von heute haben die Aktionäre sämtliche Anträge des Verwaltungsrats angenomm...
BB Biotech AG: 1 director
A director at BB Biotech AG bought 1,112 shares at 36.775CHF and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
EQS-News: Geschäftsbericht 2024: BB Biotech positioniert sich in einem...
EQS-News: BB BIOTECH AG / Schlagwort(e): Jahresbericht Geschäftsbericht 2024: BB Biotech positioniert sich in einem herausfordernden Markt mit ersten Erholungstendenzen 21.02.2025 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Medienmitteilung vom 21. Februar 2025 Geschäftsbericht 2024: BB Biotech positioniert sich in einem herausfordernden Markt mit ersten Erholungstendenzen Im 4. Quartal setzte eine strukturelle Erholung im Biotechsektor ein, getrieben durch das wiedererstarkte Anlegerinteresse an klinischen Daten, Zulas...
EQS-News: Annual Report 2024: BB Biotech positions for structural sect...
EQS-News: BB BIOTECH AG / Key word(s): Annual Report Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics 21.02.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release as at February 21, 2025 Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics 2024, especially the fourth quarter, signaled the early stage of a structural recovery in biotech, driven by renewed investor focus on clinical data, regulatory approvals, and commer...
- Baptiste Salaville
- Nicolas Thorez
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
- Baptiste Salaville
- Nicolas Thorez
EQS-News: BB Biotech: Preliminary full-year 2024 results and dividend ...
EQS-News: BB BIOTECH AG / Key word(s): Annual Results/Dividend BB Biotech: Preliminary full-year 2024 results and dividend proposal 24.01.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release as of January 24, 2025 BB Biotech: Preliminary full-year 2024 results and dividend proposal BB Biotech AG reports the following preliminary and unaudited figures for 2024: Full-year 2024: BB Biotech shares delivered a total return of -13.5% in CHF and -14.1% in EUR (including the CHF 2.00 dividend paid in March 2024). NAV perfo...
EQS-News: BB Biotech: Vorläufige Jahresergebnisse 2024 und Dividendenv...
EQS-News: BB BIOTECH AG / Schlagwort(e): Jahresergebnis/Dividende BB Biotech: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag 24.01.2025 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Medienmitteilung vom 24. Januar 2025 BB Biotech: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag Die BB Biotech AG gibt für 2024 die folgenden vorläufigen und ungeprüften Finanzergebnisse bekannt: Gesamtjahr 2024: Die Aktie von BB Biotech erzielte eine negative Gesamtrendite von 13.5% in CHF und 14.1% in EUR (einschliessli...
Edison issues report on BB Biotech (BION)
Edison Investment Research Limited Edison issues report on BB Biotech (BION) 22-Jan-2025 / 13:31 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 22 January 2025 Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (BION). BB Biotech (BION) is the largest biotech investor among its investment company peers. The company is focused on achieving long-term capital growth by investing in high-quality biotech assets developing and marketing innovative drugs. The new year has started on a very positive note for B...
- Farid Bitari
- Nicolas David
- Sinan Doganli
FME FRESENIUS MEDICAL CARE AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TEMN TEMENOS AG
TKA THYSSENKRUPP AG
CBK COMMERZBANK AG
BIO BB BIOTECH AG
EKI EKINOPS SA
MRK MERCK KGAA
BAS BASF SE
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
SY1 SYMRISE AG
KGX KION GROUP AG
ALFEN ALFEN NV
ALCUR ARCURE SA
SHA SCHAEFFLER AG
- Farid Bitari
- Nicolas David
- Sinan Doganli
FME FRESENIUS MEDICAL CARE AG
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TEMN TEMENOS AG
TKA THYSSENKRUPP AG
CBK COMMERZBANK AG
BIO BB BIOTECH AG
EKI EKINOPS SA
MRK MERCK KGAA
BAS BASF SE
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
SY1 SYMRISE AG
KGX KION GROUP AG
ALFEN ALFEN NV
ALCUR ARCURE SA
SHA SCHAEFFLER AG
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
- Luis de Toledo Heras
ATO ATOS SE
NXI NEXITY SA CLASS A
FLY SOCIETE FONCIERE LYONNAISE SA
MF WENDEL SE
EXE EXEL INDUSTRIES SA
BIO BB BIOTECH AG
MERY MERCIALYS SA
ASY ASSYSTEM SA
WHA WERELDHAVE N.V.
SWP SWORD GROUP SE
CGM CEGEDIM SA
MTU MANITOU BF SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
VID VIDRALA SA
TIETO TIETOEVRY OYJ
VIS VISCOFAN S.A.
MONT MONTEA SCA
SIGHT GENSIGHT BIOLOGICS SA
WAF SILTRONIC AG
LIGHT SIGNIFY NV
NVG NAVIGATOR COMPANY SA
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
LFDE LA FRANCAISE DE L'ENERGIE SA
TEC TECHNIPFMC PLC
XFAB X-FAB SILICON FOUNDRIES SE
SPM SAIPEM S.P.A.
- Luis de Toledo Heras
ATO ATOS SE
NXI NEXITY SA CLASS A
FLY SOCIETE FONCIERE LYONNAISE SA
MF WENDEL SE
EXE EXEL INDUSTRIES SA
BIO BB BIOTECH AG
MERY MERCIALYS SA
ASY ASSYSTEM SA
WHA WERELDHAVE N.V.
SWP SWORD GROUP SE
CGM CEGEDIM SA
MTU MANITOU BF SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
VID VIDRALA SA
TIETO TIETOEVRY OYJ
VIS VISCOFAN S.A.
MONT MONTEA SCA
SIGHT GENSIGHT BIOLOGICS SA
WAF SILTRONIC AG
LIGHT SIGNIFY NV
NVG NAVIGATOR COMPANY SA
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
LFDE LA FRANCAISE DE L'ENERGIE SA
TEC TECHNIPFMC PLC
XFAB X-FAB SILICON FOUNDRIES SE
SPM SAIPEM S.P.A.
- Martial Descoutures
- Oussema Denguir
BB Biotech AG : Q3 in negative territory, the holding continues its re...
>Net loss of CHF 157m in Q3 - BB Biotech this morning announced its Q3 2024 results. The yield on the stock was in negative territory at -9.2% in CHF and -6.7% in € and was negative for the first 9 months of the year at -11% (dividend included). The performance of the portfolio in Q3 stood at -6.6% in CHF, -4.4% in € and -0.6% in $, underperforming the Nasdaq Biotech Index (+5% in $ in the period), but was virtually flat in the first 9 months of the year at +0.3% in ...
- Martial Descoutures
- Oussema Denguir
BB Biotech AG : T3 en territoire négatif, la holding continue sa strat...
>Une perte nette de 157 MCHF au T3 - BB Biotech communique ce matin ses chiffres du T3 2024. Le rendement du titre ressort en territoire négatif à -9.2% en CHF et -6.7% en € et demeure négatif sur les 9 premiers mois de l’année à -11% (dividende inclus). La performance de son portefeuille au T3 ressort à -6.6% en CHF, -4.4% en € et -0.6% en $ sous-performant le Nasdaq Biotech Index (+5% en $ sur la période) mais ressort quasi-flat sur les 9 premiers mois de l’année à ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.